{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+750mg",
    "query": {
      "intervention": "placebo 750mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+750mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T17:36:26.264Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07301320",
      "title": "Epetraborole in Patients With Mycobacterium Abscessus Lung Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mycobacterium Abscessus Infection"
      ],
      "interventions": [
        {
          "name": "Epetraborole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kevin Winthrop",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2026-03-30",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07301320"
    },
    {
      "nct_id": "NCT04433091",
      "title": "2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter-based Ablation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "2-Hydroxybenzylamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2020-05-15",
      "completion_date": "2023-01-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04433091"
    },
    {
      "nct_id": "NCT00438932",
      "title": "Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Lanthanum Carbonate",
          "type": "DRUG"
        },
        {
          "name": "Low Phosphorus Diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Unrestricted Phosphorus Diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 16,
      "start_date": "2007-01",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2011-09-27",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00438932"
    },
    {
      "nct_id": "NCT01000506",
      "title": "Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab 750",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mepolizumab 250",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mepolizumab 75",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 621,
      "start_date": "2009-11-01",
      "completion_date": "2012-03-23",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 21,
      "location_summary": "Long Beach, California • Los Angeles, California • Riverside, California + 18 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01000506"
    },
    {
      "nct_id": "NCT02454699",
      "title": "Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "MBX400",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2015-11-10",
      "completion_date": "2017-12-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-26",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454699"
    },
    {
      "nct_id": "NCT02926651",
      "title": "Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anemia",
        "Arthritis",
        "Total Knee Arthroplasty",
        "Total Hip Arthroplasty"
      ],
      "interventions": [
        {
          "name": "Conventional Oral TXA (Tranexamic Acid)",
          "type": "DRUG"
        },
        {
          "name": "Multi-Dose Oral TXA (Tranexamic Acid)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-10",
      "completion_date": "2017-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02926651"
    },
    {
      "nct_id": "NCT05283486",
      "title": "Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcopenia",
        "Frailty",
        "Aging"
      ],
      "interventions": [
        {
          "name": "MYMD-1 600MG",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 750mg",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 900mg",
          "type": "DRUG"
        },
        {
          "name": "MYMD-1 1050mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 600mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 750mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 900mg",
          "type": "DRUG"
        },
        {
          "name": "placebo 1050mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TNF Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "65 Years to 99 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-02-01",
      "completion_date": "2023-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 3,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Baltimore, Maryland",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283486"
    },
    {
      "nct_id": "NCT03037931",
      "title": "Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure",
        "Iron-deficiency"
      ],
      "interventions": [
        {
          "name": "Ferric Carboxymaltose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Regent, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3065,
      "start_date": "2017-03-15",
      "completion_date": "2023-02-02",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 188,
      "location_summary": "Alexander City, Alabama • Auburn, Alabama • Mobile, Alabama + 157 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Auburn",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03037931"
    },
    {
      "nct_id": "NCT05562349",
      "title": "Clavulanic Acid for the Treatment of Cocaine Use Disorder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Clavulanic Acid Only Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 65,
      "start_date": "2023-05-03",
      "completion_date": "2024-07",
      "has_results": false,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Charleston, South Carolina",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05562349"
    },
    {
      "nct_id": "NCT03061474",
      "title": "Nicotinamide as an Early Alzheimer's Disease Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Nicotinamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2017-07-12",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-09-14T17:36:26.264Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Los Angeles, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03061474"
    }
  ]
}